Radiofrequency in Female Pattern Hair Loss

June 6, 2022 updated by: Hagar El Sayed, Cairo University

Efficacy of Fractional Needling Radiofrequency in Female Pattern Hair Loss, a Randomized Controlled Trial.

Pattern hair loss, also called androgenetic alopecia (AGA) is considered the most common cause of hair loss in both males and females affecting approximately 85% of males and 50% of females over 50 years of age.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

RF (Radiofrequency) based devices have also been shown to be successful in promoting hair growth, thought to occur through the induction of growth factors in the papillary dermis. Studying the effect of fractional needling radiofrequency in the treatment of female pattern hair loss will pave the way for more treatment options for this common disease.

Study Type

Interventional

Enrollment (Anticipated)

30

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 60 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Patients with female pattern hair loss

Exclusion Criteria:

  • - Pregnancy and lactation.
  • Bleeding tendency.
  • Cases who received treatment (systemic or topical) in the last 3 months before treatment.
  • Scarring alopecia.
  • Other associated causes of alopecia

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Fractional microneedling radiofrequency
Device
Other: Vivacy
Vivacy and minoxidil
Active Comparator: Fractional microneedling radiofrequency followed by minoxidil application
Device and drug
Other: Vivacy
Vivacy and minoxidil
Active Comparator: Minoxidil
Topical drug
Other: Vivacy
Vivacy and minoxidil

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Clinical examination by Sinclair scale
Time Frame: 3 months
Clinical
3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Cairo University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

June 25, 2022

Primary Completion (Anticipated)

September 15, 2022

Study Completion (Anticipated)

September 15, 2022

Study Registration Dates

First Submitted

May 20, 2022

First Submitted That Met QC Criteria

June 6, 2022

First Posted (Actual)

June 8, 2022

Study Record Updates

Last Update Posted (Actual)

June 8, 2022

Last Update Submitted That Met QC Criteria

June 6, 2022

Last Verified

June 1, 2022

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Female pattern hair loss

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Female Pattern Baldness

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Georgia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe